Skip to main content

RegMedNet is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Topics
    • CAR-T
      • Stem cells
      • Cell therapy
      • Gene therapy
      • Gene editing
    • Cancer
      • Preclinical research
      • Tissue engineering
      • 3D printing
      • Biobanking
    • Clinical trials & funding
      • Manufacturing & scale-up
      • Regulation & policy
      • Industry developments

    Follow us on social media

  • Explore content
    • News
      • The week in cell therapy
      • Spotlights
      • In Focus
      • Interviews
      • Opinion
      • Report
      • App Notes & White Papers
    • eBooks
      • Webinars
      • Podcasts
      • Videos
      • Infographics
      • Partners
      • Events
      • Events news
      • Glossary

    Follow us on social media

  • Our journals
    • Our journals
    • Journal content
    • Journal articles

    Follow us on social media

  • Register
From research to clinical production: scaling iPSC and extracellular vesicle processes 14 days 9 hours 12 mins 10 secs REGISTER NOW

eBook: Advances in CAR-T therapy

16 Aug 2024
Written by RegMedNet
Cancer CAR-T

Download peer-reviewed content and expert insights in our latest eBook. Learn more about the latest advancements in CAR-T therapies, from leveraging regulatory T-cells to enhancing the antitumor efficacy of CAR-T cells by targeting the chemokine/chemokine receptor axis.

To view this content, please register now for access

It's completely free

Register
Login

Top content

  • Cell therapy weekly: investigational AAV-based gene therapy for FSHD completes enrollment
  • Phase I/II Parkinson’s disease cell therapy trial achieves primary endpoint
  • Novel gene therapy harnesses brain’s glymphatic system for targeted delivery

Related tags

CAR-T CAR-T therapy
Previous article Next article

Related articles

13 JUN 2024 CELL THERAPY
Cell therapy weekly: Encouraging results from Phase I prostate cancer trial
21 JUN 2021 APP NOTES & WHITE PAPERS
Autologous CAR T cell manufacturing using a semiautomatic, closed, modular workflow
13 MAR 2025 CAR-T
Cell therapy weekly: US$286 million acquisition expands CAR-T manufacturing and commercialization
17 JUN 2021 THE WEEK IN CELL THERAPY
Cell therapy weekly: autologous cell therapy approach improves outcomes in heart failure
25 FEB 2021 CAR-T
Novel CAR-T therapy sees success in treatment-resistant myeloma patients
12 FEB 2021 NEWS
Cell therapy weekly: US FDA approves new cell-based gene therapy for patients with B-cell lymphoma
  • About
  • Advertising & Sponsorship
  • Expert Panel
  • Permissions & content ownership policy
  • Accessibility
  • Editorial Policies

Contact

Contact Us

Office info

RegMedNet is powered by Taylor & Francis Group

RegMedNet, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 RegMedNet